Drugs / Berahyaluronidase alfa
Berahyaluronidase alfa
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07646548 | Jun → Sep 2026 expected | — | Sanofi | Recruiting | No outcome recorded |
| Phase 1 | NCT05017012 | Sep 2021 → May 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07705165 | Aug 2026 → Jan 2028 expected | osteoarthritis, knee | Man Soo Kim | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06504394 Background | Oct 2024 → Nov 2028 expected | classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06212752 Background | Jun 2023 → Nov 2024 overdue | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05756595 Background | Jul 2020 → Dec 2022 | herpes zoster | Dove Medical Press Ltd | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Berahyaluronidase alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07705165 ↗ |
| Known as | ALT-B4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314725 ↗ |
| Known as | Berahyaluronidasa alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314725 ↗ |
| Known as | hyaluronidase PH20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05756595 ↗ |
| Modality | Protein / enzyme biologic | “the investigators, recombinant human hyaluronidase PH20 and neutral hyaluronidase (PH20 or SPAM1) of bovine testicular sperm acrosome were used to cleave macromolecular Hyaluronan.” NCT05756595 ↗ |
| Route | Subcutaneous | “Pembrolizumab (+) Berahyaluronidase alfa is a fixed-dose formulation of pembrolizumab (either Conc1 or Conc2) and berahyaluronidase alfa for SC administration.” NCT05017012 ↗ |